

Pacific Regional Strategy on HIV and other STIs 2009-2013 – M&E Framework

Global Fund - Program goal, impact and outcome indicators

GF Code	Indicator	PRSIP Code
Impact Indicator 1.1	STI prevalence among pregnant women - percentage of pregnant women with a sexually transmissible infection (Chlamydia)	Impact Indicator 3
Impact Indicator 1.2	Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy [UNGASS 24]	Impact Indicator 4
Outcome Indicator 1	Percentage of key populations, as defined by individual countries, that have received an HIV test in the last 12 months and who know their results	N/A
Outcome Indicator 2	Percentage of sexually active young women and men aged 15 to 24 years who received an HIV test in the last four years and know their results	N/A
Service delivery area 1.1	Percentage of units of blood collected from voluntary non-remunerated blood donors (VNRBD) in selected PICTs	Outcome Indicator 1.4
Prevention - Condoms 1.2	Number of condoms (disaggregated by male and female condoms, and those provided through government versus NGO systems) that are available for use in PICTs during the last 12 months.	N/A
Prevention – Testing & Counselling 2.1	Number and percentage of sites providing HIV and/or STI counselling and testing according to the Pacific Minimum Standards (including using the services of trained counsellors) among total sites providing testing and counselling.	Outcome Indicator 2.1
Prevention – Testing & Counselling 2.2	Number of people who receive HIV testing and post-counselling services (including provision of results) as per Pacific Minimum Standards.	Outcome Indicator 2.1
Prevention – Testing & Counselling 2.3	Number and percentage of laboratories reporting no break in provision of Chlamydia testing (due to stock outs of consumables, technician leave etc) lasting more than 14 days.	N/A
Prevention: Treatment of sexually transmitted infections 3.1	Number and percentage of ARV and STI treatment sites (national and provincial hospitals) reporting no stock outs of ARVs or STI drugs (as per national treatment guidelines) lasting more than 14 days.	Outcome 3.4

Prevention: Treatment of sexually transmitted infections 3.2	Number of people trained or retrained in the management of STIs	N/A
Prevention: Treatment of sexually transmitted infections 3.3	Percentage of Chlamydia cases treated among the total number testing positive within a defined population. i.e. PICT Category 1 and 2 - Asymptomatic cases referred from VCCT sites PICT Category 3 - tested ANC population including asymptomatic cases from VCCT	N/A
Treatment: Antiretroviral therapy and monitoring 3.4	Number and percentage of HIV+ people who receive CD4 monitoring in line with national/regional guidelines.	N/A
Treatment: Antiretroviral therapy and monitoring 3.5	Number of adults and children with HIV infection eligible for ART currently receiving ART in accordance with the regionally approved treatment protocol.	Impact indicator 4
Treatment: Antiretroviral therapy and monitoring 3.6	Number and percentage of HIV+ people enrolled in the HIV care program who receive care and support services that include a patient monitoring system.	N/A
Supportive environment: Reducing stigma in all settings 4.1	Number ** and percentage of selected PICTs that have a proactive, operational support network (made up of lawyers, health care workers, politicians, civil society members and HIV+ people) to provide human rights information to individuals who are HIV + people and publicly.	Outcome Indicator 4.2
HSS: Information system 5.1	Number of national programs that have cross-cutting M&E team (national officer, pharmacy, laboratory) responsible for timely, high quality data collection and reporting.	N/A
HSS: Information system 5.2	Number of national programs that are implementing routine, high quality M&E activities according to a nationally coordinated multi-year M&E plan that forms part of the National Strategic Plan (NSP) for HIV/STIs	Outcome indicator 5.1